Safe, Effective, and More Tolerable 16 Tablets Colon Prep (ABP)
Recruitment status was Active, not recruiting
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | January 5, 2009 | ||||
| Last Updated Date | January 6, 2009 | ||||
| Start Date ICMJE | January 2009 | ||||
| Estimated Primary Completion Date | January 2010 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
TOTAL COLON CLEANSING, TO BE ABLE TO PERFORM COLONOSCOPY [ Time Frame: IMMEDIATE, DURING THE COLONOSCOPY ] [ Designated as safety issue: Yes ] | ||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT00817934 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Safe, Effective, and More Tolerable 16 Tablets Colon Prep | ||||
| Official Title ICMJE | Phase III of the AB Prep Safety and Efficacy in Colon Cleansing | ||||
| Brief Summary | The purpose of this study is determine if the AB Prep (a 16 tablets colon cleansing prep), is an effective, and safe colon cleansing prep in preparation for colonoscopy, and severe constipation. |
||||
| Detailed Description | The available colon cleansing preps have issues with patient's tolerance( Abdominal pain, nausea, vomiting), and as recently noted by the FDA safety issues such a change in EKG, blood electrolytes requiring 72 hours to correct, and most recently PO4 nephropathy. The AB Prep is a 16 tablets prep that has excellent patient's tolerance efficacy, with no change in blood electrolytes or EKG. ( PhaseI (20 patients) and Phase II (200 patients) The protocol that was used is as follows: (IND application # 75,704) Protocol design for testing the safety and efficacy of the AB Prep: The AB Prep is a combination of 2 Reglan tablets (10mg each), 6 Dulcolax tablets, and 8 K-Phos Neutral tablets. The combination is given in two steps, four hours apart; the day before the colonoscopy. As before, the objective of this clinical trial is to examine the AB Prep first and foremost for safety, and second for efficacy of colon cleansing. The proposed trial is for One-Arm Study of subjects undergoing elective and therapeutic colonoscopy. Phase III: 400 patients, The selection will be random, the age probably ranging from 12 to 75 years old. The patients will have a Pre, and post procedural EKG, comprehensive (Sodium, Potassium, Creatinine, BUN, Calcium, Magnesium, Phosphate, Glucose), and vital signs. The patients with severe constipation (One bowel movement per week or more) will not be included in the study. (In our experience, those people required two days prep to achieve colon cleansing). The SRSS statistical program will be used for data collection and analysis: The end point of the study is colon cleansing, adequate enough to perform colonoscopy. The colon cleansing will be graded as follow:
A- Excellent, Totally cleansed B- Good, adequately cleansed, with need for irrigation. In addition to efficacy, we would like to check for patient's satisfaction and compliance, (Most common complaints that the patients tend to voice with the present approved colon preps). Patient's satisfaction data will be collected before the procedure and will be graded as follow:
Patient's compliance will be graded as follow:
The prep instruction will be as follows REPARATION FOR COLONOSCOPY FIVE DAYS before your procedure:
TWO DAYS before the procedure: 1. Take 2 tablets of Dulcolax at 8:00 PM. ONE DAY before the procedure:
ON THE DAY of your procedure:
Please bring these things WITH YOU to your procedure:
AFTER your procedure:
4. You may eat your normal diet after the procedure. 5. You may return to work the day after the procedure. HELPFUL HINTS FOR PATIENTS UNDERGOING COLONOSCOPY 1.Use moist wipes (baby wipes) instead of toilet paper. |
||||
| Study Type ICMJE | Observational | ||||
| Study Design ICMJE | Observational Model: Case-Only Time Perspective: Prospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Probability Sample | ||||
| Study Population | Any patient between the age of 12 and 75, who is eligible for colonoscopy. |
||||
| Condition ICMJE | Colon Cancer | ||||
| Intervention ICMJE | Drug: AB PREP
Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
Other Name: Reglan, K-Phos neutral, and Dulcolax |
||||
| Study Group/Cohort (s) | PREVENTION AND TREATMENT
PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
Intervention: Drug: AB PREP |
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Active, not recruiting | ||||
| Estimated Enrollment ICMJE | 400 | ||||
| Estimated Completion Date | January 2010 | ||||
| Estimated Primary Completion Date | January 2010 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 12 Years to 75 Years | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | United States | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00817934 | ||||
| Other Study ID Numbers ICMJE | ABBPREP1, AB1 | ||||
| Has Data Monitoring Committee | Yes | ||||
| Responsible Party | Semaan Abboud MD/ PI, Long Neck Medical Enterprises | ||||
| Study Sponsor ICMJE | Long Neck Medical Enterprises | ||||
| Collaborators ICMJE | National Institutes of Health (NIH) | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | Long Neck Medical Enterprises | ||||
| Verification Date | January 2009 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||